SCHEMBL7223145

SCHEMBL7223145

COc1ccc2c(c1)nc(SCc1ncc(C)c(OC)c1C)n2S(=O)(=O)c1ccccc1I

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRS3 P32247 2/20 0.47
CYP2C9 P11712 2/20 0.42
KMT2A Q03164 5/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 4/20 0.39
WDR5 P61964 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ATP1A1 P05023 2/20 0.39
ATP1B1 P05026 2/20 0.39
ATP1A3 P13637 2/20 0.39
ATP1B2 P14415 2/20 0.39
ATP4A P20648 2/20 0.39
ATP1A2 P50993 2/20 0.39
ATP4B P51164 2/20 0.39
ATP1B3 P54709 2/20 0.39
FXYD2 P54710 2/20 0.39
ATP1A4 Q13733 2/20 0.39
KDM4E B2RXH2 1/20 0.39
DDAH1 O94760 1/20 0.39
ABCB11 O95342 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7009207 0.89 BRS3 (0.51) BRS3CYP2C9KMT2AMEN1ALDH1A1
SCHEMBL14356237 0.85 BRS3 (0.47) BRS3CYP2C9KMT2AMEN1ALDH1A1
SCHEMBL7014064 0.82 BRS3 (0.53) BRS3CYP2C9KMT2AMEN1ALDH1A1
SCHEMBL14356254 0.82 BRS3 (0.47) BRS3CYP2C9KMT2AMEN1ALDH1A1
Lithium Ion SCHEMBL5764052 0.81 BRS3 (0.47) BRS3CYP2C9KMT2AMEN1ALDH1A1
SCHEMBL13215288 0.80 BRS3 (0.46) BRS3CYP2C9KMT2AMEN1ALDH1A1
SCHEMBL5367609 0.80 BRS3 (0.46) BRS3CYP2C9KMT2AMEN1ALDH1A1
SCHEMBL14387723 0.80 BRS3 (0.44) BRS3CYP2C9KMT2AMEN1ALDH1A1
SCHEMBL14356227 0.80 BRS3 (0.45) BRS3CYP2C9KMT2AMEN1ALDH1A1
SCHEMBL5446485 0.80 BRS3 (0.44) BRS3CYP2C9KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6559167-B1 Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under REGENTS OF THE UNIVERSITY OF CALIFORNIA 2003-05-06 US disclosed